News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-404

I think you would find that he is not unique. Often the entire market valuation is used rather than the section specific to the company. It is called selling a dream, all tech companies do it.
The failure here is not about the 16 figure which would probably be the case in 10 or so years. The failure in my view is not looking after the share price so he can do appropriate CR at much higher valuation thus not dilution us all into oblivion.
Pop across to RAP and see what RAP claim its market to be , it would shock your socks off and to me it is all a pipe dream but the company manages it market cap much better.